Literature DB >> 33375410

The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19.

Maksim V Baranov1, Frans Bianchi1, Geert van den Bogaart1,2.   

Abstract

The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent viral invasion by inhibiting host cell proteases, the same proteases are critical for antigen presentation leading to T cell activation and there is good evidence from both in vitro studies and the clinic that apilimod blocks antiviral immune responses. We therefore warn that the immunosuppression observed in many COVID-19 patients might be aggravated by apilimod.

Entities:  

Keywords:  COVID-19; LAM-002A; PIKfyve; SARS-CoV-2; STA-5326; apilimod

Year:  2020        PMID： 33375410     DOI： 10.3390/cells10010030

Source DB:  PubMed          Journal:  Cells        ISSN： 2073-4409            Impact factor:   6.600


  11 in total

1.  Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses.

Authors:  David H Drewry; Frances M Potjewyd; Armin Bayati; Jeffery L Smith; Rebekah J Dickmander; Stefanie Howell; Sharon Taft-Benz; Sophia M Min; Mohammad Anwar Hossain; Mark Heise; Peter S McPherson; Nathaniel J Moorman; Alison D Axtman
Journal:  J Med Chem       Date:  2022-09-16       Impact factor: 8.039

2.  Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice.

Authors:  Ana C Puhl; Giovanni F Gomes; Samara Damasceno; Ethan J Fritch; James A Levi; Nicole J Johnson; Frank Scholle; Lakshmanane Premkumar; Brett L Hurst; Felipe LeeMontiel; Flavio P Veras; Sabrina S Batah; Alexandre T Fabro; Nathaniel J Moorman; Boyd L Yount; Rebekah Dickmander; Ralph Baric; Kenneth H Pearce; Fernando Q Cunha; José C Alves-Filho; Thiago M Cunha; Sean Ekins
Journal:  bioRxiv       Date:  2021-12-20

Review 3.  Perspectives and potential approaches for targeting neuropilin 1 in SARS-CoV-2 infection.

Authors:  Svetlana P Chapoval; Achsah D Keegan
Journal:  Mol Med       Date:  2021-12-27       Impact factor: 6.376

4.  A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry.

Authors:  Miao Xu; Manisha Pradhan; Kirill Gorshkov; Jennifer D Petersen; Min Shen; Hui Guo; Wei Zhu; Carleen Klumpp-Thomas; Sam Michael; Misha Itkin; Zina Itkin; Marco R Straus; Joshua Zimmerberg; Wei Zheng; Gary R Whittaker; Catherine Z Chen
Journal:  bioRxiv       Date:  2021-10-05

Review 5.  Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review.

Authors:  Lei Zhao; Song Li; Wu Zhong
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

6.  Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice.

Authors:  Ana C Puhl; Giovanni F Gomes; Samara Damasceno; Ethan J Fritch; James A Levi; Nicole J Johnson; Frank Scholle; Lakshmanane Premkumar; Brett L Hurst; Felipe Lee-Montiel; Flavio P Veras; Sabrina S Batah; Alexandre T Fabro; Nathaniel J Moorman; Boyd L Yount; Rebekah J Dickmander; Ralph S Baric; Kenneth H Pearce; Fernando Q Cunha; José C Alves-Filho; Thiago M Cunha; Sean Ekins
Journal:  ACS Omega       Date:  2022-08-29

Review 7.  The Key Role of Lysosomal Protease Cathepsins in Viral Infections.

Authors:  Melania Scarcella; Danila d'Angelo; Mariangela Ciampa; Simona Tafuri; Luigi Avallone; Luigi Michele Pavone; Valeria De Pasquale
Journal:  Int J Mol Sci       Date:  2022-08-13       Impact factor: 6.208

8.  Analysis of COVID-19 on Diagnosis, Vaccine, Treatment, and Pathogenesis with Clinical Scenarios.

Authors:  Daniel Tellez; Sujay Dayal; Phong Phan; Ajinkya Mawley; Kush Shah; Gabriel Consunji; Cindy Tellez; Kimberly Ruiz; Rutuja Sabnis; Surbi Dayal; Vishwanath Venketaraman
Journal:  Clin Pract       Date:  2021-05-19

9.  Entrectinib-A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells.

Authors:  Alejandro Peralta-Garcia; Mariona Torrens-Fontanals; Tomasz Maciej Stepniewski; Judith Grau-Expósito; David Perea; Vikram Ayinampudi; Maria Waldhoer; Mirjam Zimmermann; María J Buzón; Meritxell Genescà; Jana Selent
Journal:  Int J Mol Sci       Date:  2021-12-18       Impact factor: 5.923

Review 10.  SARS-CoV-2 Antiviral Therapy.

Authors:  Kaiming Tao; Philip L Tzou; Janin Nouhin; Hector Bonilla; Prasanna Jagannathan; Robert W Shafer
Journal:  Clin Microbiol Rev       Date:  2021-07-28       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.